Key facts
- ACELYRIN, Inc. has 20 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 21 May 2025.
$0
Shares: 0
Insiders: 0
$0
Shares: 0
Insiders: 0
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Madison Avenue Partners, LP |
13D/G
|
— |
5.1%
|
5,089,260
|
$12,468,687 | $0 | 29 Apr 2025 | |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
— |
4.7%
|
4,714,402
|
$11,550,285 | $0 | 31 Dec 2024 | |
| T. Rowe Price Investment Management, Inc. |
13D/G
|
— |
4.6%
|
4,651,030
|
$11,395,024 | -$20,141,680 | 28 Feb 2025 | |
| CITADEL ADVISORS LLC |
13D/G
|
Kenneth Griffin |
4.2%
|
4,218,748
|
$10,335,933 | $0 | 31 Dec 2024 | |
| Westlake BioPartners Fund II, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
9,790,729
|
$72,519,930 | — | 09 May 2023 | |
| Shao-Lee Lin |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
1,995,942
mixed-class rows
|
$10,488,913 | — | 01 Apr 2024 | |
| Paul Peloso |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
160,644
|
$1,189,890 | — | 04 Oct 2023 | |
| Ronald Oyston |
3/4/5
|
Chief People Officer |
—
mixed-class rows
|
264,932
mixed-class rows
|
$1,047,039 | — | 09 Jan 2024 | |
| Melanie Gloria |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
314,328
mixed-class rows
|
$582,378 | — | 23 May 2024 | |
| Gil M. Labrucherie |
3/4/5
|
CFO and CBO |
—
mixed-class rows
|
381,055
mixed-class rows
|
$348,226 | — | 31 Aug 2024 | |
| Sanam Pangali |
3/4/5
|
CLO & Head of People |
—
mixed-class rows
|
403,014
mixed-class rows
|
$331,468 | — | 23 May 2024 | |
| Mardi Dier |
3/4/5
|
CFO and CBO |
—
mixed-class rows
|
91,657
mixed-class rows
|
$47,634 | — | 09 May 2023 | |
| Mina Kim |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
1,195,856
|
— | — | 21 May 2025 | |
| Shephard Mpofu |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
328,860
|
— | — | 21 May 2025 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| AyurMaya Capital Management Company, LP | SLRN | Common Stock, par value $0.00001 per share ("Common Stock") | Disposed to Issuer | -100% | -9,334,735 | 0 | 21 May 2025 | See footnotes | ||
| Mina Kim | SLRN | Common Stock | Disposed to Issuer | -100% | -770,833 | 0 | 21 May 2025 | Direct | ||
| Mina Kim | SLRN | Common Stock | Award | 13.1% | 89,526 | 770,833 | 21 May 2025 | Direct | ||
| Mina Kim | SLRN | Employee Stock Option (right to buy) | Disposed to Issuer | -100% | -1,833,915 | 0 | 21 May 2025 | Direct | ||
| Bruce C. Cozadd | SLRN | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -298,835 | 0 | 21 May 2025 | Direct | ||
| Amar Murugan | SLRN | Common Stock | Disposed to Issuer | -100% | -121,587 | 0 | 21 May 2025 | Direct | ||
| Amar Murugan | SLRN | Employee Stock Option (right to buy) | Disposed to Issuer | -100% | -525,000 | 0 | 21 May 2025 | Direct | ||
| Beth C. Seidenberg | SLRN | Common Stock | Disposed to Issuer | -100% | -9,790,729 | 0 | 21 May 2025 | See footnote | ||
| Beth C. Seidenberg | SLRN | Common Stock | Disposed to Issuer | -100% | -60,000 | 0 | 21 May 2025 | Direct | ||
| Beth C. Seidenberg | SLRN | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -115,401 | 0 | 21 May 2025 | Direct | ||
| Shephard Mpofu | SLRN | Common Stock | Disposed to Issuer | -100% | -121,789 | 0 | 21 May 2025 | Direct | ||
| Shephard Mpofu | SLRN | Employee Stock Option (right to buy) | Disposed to Issuer | -100% | -590,304 | 0 | 21 May 2025 | Direct | ||
| Gosebruch Henry O | SLRN | Common Stock | Disposed to Issuer | -100% | -50,000 | 0 | 21 May 2025 | Direct | ||
| Gosebruch Henry O | SLRN | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -247,608 | 0 | 21 May 2025 | Direct | ||
| Patrick Machado | SLRN | Common Stock | Disposed to Issuer | -100% | -14,675 | 0 | 21 May 2025 | See footnote | ||
| Patrick Machado | SLRN | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -270,849 | 0 | 21 May 2025 | Direct | ||
| Dawn Svoronos | SLRN | Common Stock | Disposed to Issuer | -100% | -15,000 | 0 | 21 May 2025 | Direct | ||
| Dawn Svoronos | SLRN | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -270,851 | 0 | 21 May 2025 | Direct | ||
| Daniel J. Becker | SLRN | Common Stock | Disposed to Issuer | -100% | -2,999 | 0 | 21 May 2025 | Direct | ||
| Daniel J. Becker | SLRN | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -115,401 | 0 | 21 May 2025 | Direct | ||
| Lynn A. Tetrault | SLRN | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -133,635 | 0 | 21 May 2025 | Direct |